Impact Biomedical, Inc., a wholly owned subsidiary of DSS, Inc.
(NYSE American: DSS) along with its scientific research partner
Global Research and Discovery Group Sciences, (GRDG) announced
today a project that is designed to take plastics in a whole new
direction with the development of what we call Bio-plastics.
Bio-plastics under development are designed to make everyday
objects resistant to viruses, and also gentler to the planet.
Building off of existing research Daryl Thompson, founder of
GRDG Sciences, explored the globe searching for ways to develop new
types of microbial plastics that break down and decompose quicker
than current plastics.
“We basically went anywhere and everywhere looking at plants and
animals that don’t have viruses actively growing on them,” said
Thompson. “We traveled from swamps and rivers, to the grovelands,
to the depths of the oceans. We knew that nature has a way of
protecting itself, we just had to look closer and then find a way
to incorporate what we found into man-made science.”
Thompson and his team focused on different types of biological
sources that naturally prevent the unwanted growth of harmful
bacteria or viruses.
“By isolating and adding these natural, biological compounds to
plastics, we are attempting to reinvent plastics to make them be
not only more bio-friendly, but also more bio-compatible,” said
Thompson.
Early TestingEarly testing results on the new
bioplastic prototypes is promising. The anti-microbial bioplastics
reduced SARS-CoV-2 by more than 1 log fold (90% reduction) by 30
minutes and approximately 2 log fold (99% reduction) in 2 hours.
These antimicrobial properties would be of obvious benefit in
assisting to sterilize surfaces — especially as the world continues
to feel the effects of the coronavirus pandemic.
As testing continues, the diverse uses of bioplastics are nearly
limitless, from cups to countertops and even paper. The bioplastics
could easily be integrated into all types of contexts, including
health care, public spaces, and home settings, effectively always
helping to protect people at every turn.
These early results are welcome news for GRDG Chief Scientific
Advisor Dr. Roscoe M. Moore Jr., United States Assistant Surgeon
General (Retired) and former Epidemic Intelligence Service (EIS)
Officer at the U.S. Centers for Disease Control and Prevention.
“Think of the lives that could be protected and saved if every
surface effectively cleans itself between uses,” he said. “One of
the ways a vast number of viruses are spread is through touching
contaminated surfaces and then touching your face. If we can stop
the viral threat on the surface, the number of people who become
ill will fall.”
Better for the PlanetA promising secondary
component of these bio-plastics may prove to have an even larger
global impact. Inserting these natural compounds into the plastics
makes designed for improved degradation.
It is estimated that there are currently 5.25 trillion pieces of
macro and micro plastics in the world’s oceans, weighing 269,000
metric tons. Every day, around 8 million new pieces of plastic
enter the ocean. The National Geographic Society reported in July
2020 that the total amount of plastics in the ocean could nearly
triple by 2040.
“The bio-plastic models we are working on naturally break down
easier and sooner than current plastics. This will help lower the
number of plastics that make it into the ocean,” said Frank
Heuszel, President of Impact Biomedical, Inc. “That’s good news for
the planet.”
Growing MarketThese results of these innovative
GRDG microbial bioplastics comes on the heels of a 2020 Bloomberg
article that reported the antimicrobial market will balloon to
$17.55 billion by 2026 because of rising safety concerns.
Companies such as BASF, which is expanding its production plant
in anticipation of the rise; Dunmore Corporation, Biocote, PolyOne,
Microban, DOW and others are all key players in the antimicrobial
packaging market, which is a prime area of focus for GRDG as it
continues to refine its bioplastics technology and seek
partnerships for the general market.
About Impact BioMedical, Inc.Impact BioMedical,
Inc. ("Impact BioMedical") is a wholly owned subsidiary of DSS.
Impact BioMedical strives to leverage its scientific know-how and
intellectual property rights to provide solutions that have been
plaguing the biomedical field for decades. By tapping into the
scientific expertise of GRDG Sciences, LLC, Impact BioMedical
pledges to undertake a concerted effort in the R&D, drug
discovery and development for the prevention, inhibition, and
treatment of neurological, oncological and immuno related diseases.
For more information on Impact BioMedical
visit http://impbio.com/.
About DSS, Inc.DSS is a multinational company
operating business segments in blockchain security, direct
marketing, healthcare, consumer packaging, real estate, renewable
energy, securitized digital assets, securities trading and fund
management, and banking, lending, and finance. Its business model
is based on a distribution sharing system in which shareholders
receive shares in its subsidiaries as DSS strategically unlocks
value through IPO spin offs. Under new leadership since 2019, DSS
has built the necessary foundation for sustainable growth through
the acquisition and formation of a diversified portfolio of
companies positioned to drive profitability in five high-growth
sectors. These companies offer innovative, flexible, and real-world
solutions that not only meet customer needs, but create sustainable
value and opportunity for transformation.
For more information on DSS
visit http://www.dssworld.com.
Investor Contact:Dave Gentry, CEORedChip Companies
Inc.407-491-4498Dave@redchip.com
Safe Harbor DisclosureThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Such forward-looking
statements include, but are not limited to, statements related to
the Company's intended use of proceeds and other statements that
are not historical facts. Forward-looking statements are based on
management's current expectations and are subject to risks and
uncertainties that may cause actual results or events to differ
materially from those projected. These risks and uncertainties,
many of which are beyond our control, include: risks relating to
our growth strategy; our ability to obtain, perform under and
maintain financing and strategic agreements and relationships;
risks relating to the results of development activities; our
ability to attract, integrate and retain key personnel; our need
for substantial additional funds; patent and intellectual property
matters; competition; as well as other risks described in our SEC
filings, including, without limitation, our reports on Forms 8-K,
10-K and 10-Q, all of which can be obtained on the SEC website at
www.sec.gov. Readers are cautioned not to place undue reliance on
the forward-looking statements, which speak only as of the date on
which they are made and reflect management's current estimates,
projections, expectations, and beliefs. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions, or circumstances on which any such statement is based,
except as required by law.
DSS (AMEX:DSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
DSS (AMEX:DSS)
Historical Stock Chart
From Jul 2023 to Jul 2024